Literature DB >> 11120956

Molecular modeling approach to understanding the mode of action of L-nucleosides as antiviral agents.

K Lee1, C K Chu.   

Abstract

A series of unnatural L-nucleosides such as 3TC, FTC and L-FMAU have been found to be potent antiviral agents. The mode of action of L-nucleosides has been found to be similar to that of D-nucleosides as antiviral agents, despite their unnatural stereochemistry, that is, nucleotide formation by kinases followed by interaction with the reverse transcriptase (RT) of HIV or DNA polymerase. To date, the mode of action of nucleoside inhibitors at the molecular level with respect to the active conformations of the 5'-triphosphates as well as the interaction with the RT is not known. Recently, the X-ray crystal structure of the RT-DNA-dTTP catalytic complex has been reported. Computer modeling has been performed for several pairs of D- and L-nucleoside inhibitors using the HIV-1 RT model and crystal coordinate data from a subset of the protein surrounding the deoxynucleoside triphosphate (dNTP) binding pocket region. Results from our modeling studies of D-/L-zidovudine, D-/L-3TC, D-/L-dideoxycytosine triphosphates, dTTP and dCTP show that their binding energies correlate with the reported 50% effective concentrations. Modeling results are also discussed with respect to favorable conformations of each inhibitor at the dNTP site in the polymerization process. Additionally, the clinically important M184V mutation, which confers resistance against 3TC and FTC, was studied with our modeling system. The binding energy patterns of nucleoside inhibitors at the M184V mutation site correlate with the reported antiviral data.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11120956      PMCID: PMC90251          DOI: 10.1128/AAC.45.1.138-144.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  37 in total

1.  2',3'-Dideoxycytidine: regulation of its metabolism and anti-retroviral potency by natural pyrimidine nucleosides and by inhibitors of pyrimidine nucleotide synthesis.

Authors:  J Balzarini; D A Cooney; M Dalal; G J Kang; J E Cupp; E DeClercq; S Broder; D G Johns
Journal:  Mol Pharmacol       Date:  1987-12       Impact factor: 4.436

2.  Potent and selective in vitro activity of 3'-deoxythymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine) against human immunodeficiency virus.

Authors:  T S Lin; R F Schinazi; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1987-09-01       Impact factor: 5.858

3.  Comparative activity of 2',3'-saturated and unsaturated pyrimidine and purine nucleosides against human immunodeficiency virus type 1 in peripheral blood mononuclear cells.

Authors:  C K Chu; R F Schinazi; B H Arnold; D L Cannon; B Doboszewski; V B Bhadti; Z P Gu
Journal:  Biochem Pharmacol       Date:  1988-10-01       Impact factor: 5.858

4.  Unusual structural features of 2',3'-dideoxycytidine, an inhibitor of the HIV (AIDS) virus.

Authors:  G I Birnbaum; T S Lin; W H Prusoff
Journal:  Biochem Biophys Res Commun       Date:  1988-02-29       Impact factor: 3.575

5.  In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine.

Authors:  R Yarchoan; H Mitsuya; R V Thomas; J M Pluda; N R Hartman; C F Perno; K S Marczyk; J P Allain; D G Johns; S Broder
Journal:  Science       Date:  1989-07-28       Impact factor: 47.728

6.  Broad spectrum antiretroviral activity of 2',3'-dideoxynucleosides.

Authors:  J E Dahlberg; H Mitsuya; S B Blam; S Broder; S A Aaronson
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

7.  3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.

Authors:  H Mitsuya; K J Weinhold; P A Furman; M H St Clair; S N Lehrman; R C Gallo; D Bolognesi; D W Barry; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

8.  Correlation between preferred sugar ring conformation and activity of nucleoside analogues against human immunodeficiency virus.

Authors:  P Van Roey; J M Salerno; C K Chu; R F Schinazi
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

9.  3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents.

Authors:  P Herdewijn; J Balzarini; E De Clercq; R Pauwels; M Baba; S Broder; H Vanderhaeghe
Journal:  J Med Chem       Date:  1987-08       Impact factor: 7.446

10.  Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).

Authors:  R Yarchoan; C F Perno; R V Thomas; R W Klecker; J P Allain; R J Wills; N McAtee; M A Fischl; R Dubinsky; M C McNeely
Journal:  Lancet       Date:  1988-01-16       Impact factor: 79.321

View more
  5 in total

1.  Synthesis and anti-HIV activity of D- and L-thietanose nucleosides.

Authors:  Hyunah Choo; Xin Chen; Vikas Yadav; Jianing Wang; Raymond F Schinazi; Chung K Chu
Journal:  J Med Chem       Date:  2006-03-09       Impact factor: 7.446

2.  Differential maintenance of the M184V substitution in the reverse transcriptase of human immunodeficiency virus type 1 by various nucleoside antiretroviral agents in tissue culture.

Authors:  Marco Petrella; Maureen Oliveira; Daniela Moisi; Mervi Detorio; Bluma G Brenner; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

3.  Antiviral resistance and hepatitis B therapy.

Authors:  Marc G Ghany; Edward C Doo
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

4.  Fluorinated Nucleosides: Synthesis and Biological Implication.

Authors:  Peng Liu; Ashoke Sharon; Chung K Chu
Journal:  J Fluor Chem       Date:  2008-09       Impact factor: 2.050

5.  The carboxyl-terminus of human immunodeficiency virus type 2 circulating recombinant form 01_AB capsid protein affects sensitivity to human TRIM5α.

Authors:  Tadashi Miyamoto; Emi E Nakayama; Masaru Yokoyama; Shiro Ibe; Shunpei Takehara; Ken Kono; Yoshiyuki Yokomaku; Massimo Pizzato; Jeremy Luban; Wataru Sugiura; Hironori Sato; Tatsuo Shioda
Journal:  PLoS One       Date:  2012-10-19       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.